Analysts expect Verastem to post earnings of ($0.46) per share and revenue of $22.8790 million for the quarter. Verastem Stock Down 3.5%VSTM stock opened at $6.01 on Thursday. Following the completion of the transaction, the chief executive officer owned 591,242 shares of the company’s stock, valued at approximately $2,471,391.56. Alliance Global Partners reiterated a “buy” rating on shares of Verastem in a research note on Friday, May 8th. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.